Interestingly, both tumor cell lines express the wild type forms of BRAF and p53, offering the possibility to be used as targets for alternative drugs for the treatment of melanoma cells with activating mutations of the BRAF and Ras oncogenes. This evidence concerns the gene BRAF and melanoma.